scholarly journals Effect of Porcine Placenta Extract Supplement on Skin Condition in Healthy Adult Women: A Randomized, Double-Blind Placebo-Controlled Study

Nutrients ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1671
Author(s):  
Masumi Nagae ◽  
Maki Nagata ◽  
Mitsuhiro Teramoto ◽  
Masayuki Yamakawa ◽  
Takahiro Matsuki ◽  
...  
Keyword(s):  
Winter Season ◽  
Oral Intake ◽  
Skin Condition ◽  
Quality Parameters ◽  
Controlled Study ◽  
Adult Women ◽  
Health Food ◽  
Food Ingredient ◽  
Double Blind ◽  
Skin Quality

Placenta extract has been used as a component of ointments for skin dryness and beautification. However, little is known about the effect of oral intake of placenta extract on skin condition. The current study aimed to clinically explore the effect of oral intake of porcine placenta extract on human skin quality. A randomized controlled double-blind trial was performed on healthy women aged 40–59 years (n = 20), who were randomly assigned to receive either placebo or 200 mg of porcine placenta extract once daily for 4 weeks from 28 January 2019 to 25 February 2019. Skin quality parameters and the Simplified Menopausal Index (SMI) were assessed at baseline and after 4 weeks. After 4 weeks, three parameters of skin quality were significantly improved in the porcine placenta group compared with the placebo group. These results suggest that porcine placenta extract can be used as a health food ingredient to maintain humans’ skin condition in the dry winter season.

ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study

2008 ◽  
Vol 12 (6) ◽  
pp. 268-275 ◽  
Author(s):  
Aditya K. Gupta ◽  
Richard G. Langley ◽  
Charles Lynde ◽  
Kirk Barber ◽  
Wayne Gulliver ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Phase Ii ◽  
Life Quality ◽  
Skin Condition ◽  
Controlled Study ◽  
Double Blind ◽  
Plaque Type ◽  
Psoriasis Disability Index ◽  
Stable Plaque

Background: Psoriasis is a chronic skin condition that can negatively affect a patient's quality of life (QoL), often hindering social functioning. ISA247, a novel psoriatic agent, has shown clinical efficacy in moderate to severe psoriasis sufferers, but its effect on QoL is currently not reported. Objective: The objective of this study was to assess the effect of ISA247 on the QoL in patients with stable, plaque-type psoriasis. Methods: A phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study assessed the effects of ISA247 doses of 0.5 mg/kg/d ( n = 77) or 1.5 mg/kg/d ( n = 83) compared with placebo ( n = 41) for 12 weeks. QoL was assessed using the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index (PDI) scales. Results: ISA247 treatment (pooled groups) significantly improved QoL scores as assessed by both the DLQI and the PDI compared with those receiving placebo ( p < .05). Treatment with the higher dose of 1.5 mg/kg/d demonstrated a significantly greater response to many of the QoL scales compared with the 0.5 mg/kg/d group ( p < .05). Conclusions: ISA247 appears to improve the QoL while also providing effective treatment for chronic, moderate to severe, plaque-type psoriasis.

scholarly journals A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for Evaluation of the Efficacy and Safety of DKB114 on Reduction of Uric Acid in Serum

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3794
Author(s):  
Yu Hwa Park ◽  
Do Hoon Kim ◽  
Jung Suk Lee ◽  
Hyun Il Jeong ◽  
Kye Wan Lee ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Uric Acid ◽  
Placebo Group ◽  
Serum Uric Acid ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Food Ingredient ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Significant Difference

This study sought to investigate the antihyperuricemia efficacy and safety of DKB114 (a mixture of Chrysanthemum indicum Linn flower extract and Cinnamomum cassia extract) to evaluate its potential as a dietary supplement ingredient. This clinical trial was a randomized, 12-week, double-blind, placebo-controlled study. A total of 80 subjects (40 subjects with an intake of DKB114 and 40 subjects with that of placebo) who had asymptomatic hyperuricemia (7.0–9.0 mg/dL with serum uric acid) was randomly assigned. No significant difference between the DKB114 and placebo groups was observed in the amount of uric acid in serum after six weeks of intake. However, after 12 weeks of intake, the uric acid level in serum of subjects in the DKB114 group decreased by 0.58 ± 0.86 mg/dL and was 7.37 ± 0.92 mg/dL, whereas that in the placebo group decreased by 0.02 ± 0.93 mg/dL and was 7.67 ± 0.89 mg/dL, a significant difference (p = 0.0229). In the analysis of C-reactive protein (CRP) change, after 12 weeks of administration, the DKB114 group showed an increase of 0.05 ± 0.27 mg/dL (p = 0.3187), while the placebo group showed an increase of 0.10 ± 0.21 mg/dL (p = 0.0324), a statistically significant difference (p = 0.0443). In the analysis of amount of change in apoprotein B, after 12 weeks of administration, the DKB114 group decreased by 4.75 ± 16.69 mg/dL (p = 0.1175), and the placebo group increased by 3.13 ± 12.64 mg/dL (p = 0.2187), a statistically significant difference between the administration groups (p = 0.0189). In the clinical pathology test, vital signs and weight measurement, and electrocardiogram test conducted for safety evaluation, no clinically significant difference was found between the ingestion groups, confirming the safety of DKB114. Therefore, it may have potential as a treatment for hyperuricemia and gout. We suggest that DKB114 as a beneficial and safe food ingredient for individuals with high serum uric acid. Trial registration (CRIS.NIH. go. Kr): KCT0002840.

scholarly journals Effects of Yeast Mannan Which Promotes Beneficial Bacteroides on the Intestinal Environment and Skin Condition: A Randomized, Double-Blind, Placebo-Controlled Study

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3673
Author(s):  
Reiko Tanihiro ◽  
Katsuhisa Sakano ◽  
Shunsuke Oba ◽  
Chikako Nakamura ◽  
Kohji Ohki ◽  
...  
Keyword(s):  
Skin Condition ◽  
Water Soluble ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Intestinal Environment ◽  
Healthy Female ◽  
Soluble Polysaccharide ◽  
Bacteroides Ovatus

Yeast mannan (YM) is an indigestible water-soluble polysaccharide of the yeast cell wall. In vitro fecal fermentation studies showed that YM could exhibit a notable prebiotic effect. The aim of this randomized, double-blind, placebo-controlled study was to assess the efficacy of YM intake on the intestinal environment and skin condition. One hundred and ten healthy female subjects aged 30–49 years were supplemented with YM or placebo for eight weeks. Skin dryness was set as the primary endpoint. No side effects were observed during the study. Microbiota analyses revealed that YM intake selectively increased the relative abundance of Bacteroides thetaiotaomicron and Bacteroides ovatus compared to that by placebo. Feces and urine analyses showed that YM intake lowered the concentration of fecal p-cresol, indole, and skatole, and elevated urinal equol levels compared to those in placebo. Furthermore, YM supplementation ameliorated subjective skin dryness. This study suggests that YM intake could promote beneficial Bacteroides and improve the intestinal environment and skin condition.

Chronic, But Not Acute, Oral L-Arginine Supplementation Attenuates Exercise-Induced Ammonia Accumulation in Healthy Young Men: A Randomised, Double-Blind, Cross-Over, Placebo-Controlled Trial

2021 ◽  
Author(s):  
Ayano Hiratsu ◽  
Yusei Tataka ◽  
Saki Namura ◽  
Chihiro Nagayama ◽  
Yuka Hamada ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Effect Size ◽  
Performance Test ◽  
Young Men ◽  
Oral Intake ◽  
Cycling Performance ◽  
Controlled Study ◽  
Double Blind ◽  
Ammonia Accumulation ◽  
Arginine Supplementation

Abstract Background This study examined the effects of a single and continuous oral intake of L-arginine supplementation on blood metabolites and exercise performance. Methods Sixteen healthy young men (mean ± standard deviation, 23 ± 3 years) participated in a randomised, double-blind, cross-over, placebo-controlled study. For the acute trials, the participants consumed 200 mL of water containing either L-arginine (5 g) or placebo (L-arginine was replaced with dextrin) and performed cycling exercise at 75 % of heart rate reserve for 60 min, followed by a 15-min cycling performance test. The participants continued to consume each designated supplement twice a day for 13 days. For the chronic trials, the participants repeated the same protocol as the acute trials at day 15. After a 14-day washout period, the participants changed the supplement and repeated the same protocol as above. The linear mixed model was used to examine between-trial differences over the 1-day or 2-week intervention for outcome variables. Results Plasma ammonia concentrations were lower in the chronic arginine (43.5 ± 27.6 µmol/L) trial than in both acute arginine (52.1 ± 36.3 µmol/L, 95% confidence interval − 15.907 to − 1.318 µmol/L, Effect size = 0.262) and placebo (51.1 ± 32.7 µmol/L, 95% confidence interval − 14.932 to − 0.343 µmol/L, Effect size = 0.249) trials (p < 0.05). No differences were found in mean power output during the performance test between the chronic arginine (169.3 ± 8.6 W) and placebo (168.8 ± 2.3 W) trials (p > 0.05). Conclusions These results indicate that a continuous oral intake of L-arginine supplementation attenuated ammonia accumulation, but this did not influence cycling performance.

A Randomized, Double-blind, Placebo-controlled Study on the Clinical Efficacy of Oral Treatment with DermaVite™ on Ageing Symptoms of the Skin

2005 ◽  
Vol 33 (3) ◽  
pp. 267-272 ◽  
Author(s):  
E Thom
Keyword(s):  
Oral Treatment ◽  
Controlled Study ◽  
Bark Extract ◽  
Skin Thickness ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Significant Difference ◽  
Tactile Roughness ◽  
Study Participants ◽  
Skin Quality

In this double-blind, placebo-controlled study, 40 women with ageing symptoms of the skin were randomized to receive DermaVite™, a new preparation containing marine proteins, α-lipoic acid, pine bark extract, vitamins and minerals ( n = 20), or placebo ( n = 20) twice daily for 6 months. Objective measurements of skin thickness and elasticity, together with subjective clinical assessments of various parameters (fine wrinkles, coarse wrinkles, tactile roughness and teleangiectasia) were used to evaluate changes after 2, 4 and 6 months' treatment. Self-evaluations were also made by the study participants. There was a significant improvement in skin quality in both objective and subjective parameters after treatment with Dermavite™ compared with placebo. Participants' self-evaluations also showed a statistically significant difference in favour of the active treatment. The treatment was very well tolerated. Based on this efficacy and tolerability study, DermaVite™ can be considered a suitable therapy for ageing symptoms of the skin.

scholarly journals Clinical effectiveness of the sequential 4-channel NMES compared with that of the conventional 2-channel NMES for the treatment of dysphagia in a prospective double-blind randomized controlled study

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Kyoung-Ho Seo ◽  
Joonyoung Jang ◽  
Eun Gyeong Jang ◽  
Yulhyun Park ◽  
So Young Lee ◽  
...  
Keyword(s):  
Neuromuscular Electrical Stimulation ◽  
Oral Intake ◽  
Clinical Effectiveness ◽  
Controlled Study ◽  
Double Blind ◽  
Registration Number ◽  
Md Anderson ◽  
Functional Oral Intake Scale ◽  
Anderson Dysphagia Inventory

Abstract Background To date, conventional swallowing therapies and 2-channel neuromuscular electrical stimulation (NMES) are standard treatments for dysphagia. The precise mechanism of 2-channel NMES treatment has not been determined, and there are controversies regarding the efficacy of this therapy. The sequential 4-channel NMES was recently developed and its action is based on the normal contractile sequence of swallowing-related muscles. Objective To evaluate and compare the rehabilitative effectiveness of the sequential 4-channel NMES with that of conventional 2-channel NMES. Methods In this prospective randomized case–control study, 26 subjects with dysphagia were enrolled. All participants received 2- or 4-channel NMES for 2–3 weeks (minimal session: 7 times, treatment duration: 300–800 min). Twelve subjects in the 4-channel NMES group and eleven subjects in the 2-channel NMES group completed the intervention. Initial and follow-up evaluations were performed using the videofluoroscopic dysphagia scale (VDS), the penetration-aspiration scale (PAS), the MD Anderson dysphagia inventory (MDADI), the functional oral intake scale (FOIS), and the Likert scale. Results The sequential 4-channel NMES group experienced significant improvement in their VDS (oral, pharyngeal, and total), PAS, FOIS, and MDADI (emotional, functional, and physical subsets) scores, based on their pretreatment data. VDS (oral, pharyngeal, and total) and MDADI (emotional and physical subsets) scores, but not PAS and FOIS scores, significantly improved in the 2-channel NMES group posttreatment. When the two groups were directly compared, the 4-channel NMES group showed significant improvement in oral and total VDS scores. Conclusions The sequential 4-channel NMES, through its activation of the suprahyoid and thyrohyoid muscles, and other infrahyoid muscles mimicking physiological activation, may be a new effective treatment for dysphagia. Trial registration: clinicaltrial.gov, registration number: NCT03670498, registered 13 September 2018, https://clinicaltrials.gov/ct2/show/NCT03670498?term=NCT03670498&draw=2&rank=1.

scholarly journals Beneficial effects of corn syrup containing maltobionic acid on bone density in healthy Japanese adult women: A randomized double-blind placebo-controlled study

2019 ◽  
Vol 9 (9) ◽  
pp. 606
Author(s):  
Daiki Suehiro ◽  
Ken Fukami ◽  
Tsuyoshi Takara
Keyword(s):  
Bone Mineral ◽  
Peripheral Blood ◽  
Blood Test ◽  
Controlled Study ◽  
Adult Women ◽  
Mineral Density ◽  
Double Blind ◽  
Corn Syrup ◽  
Double Blind Placebo ◽  
Test Food

Background: Osteoporosis is characterized by reduced bone mineral density (BMD) and increased fracture risk, with a higher incidence in post-menopausal women. This study aimed to evaluate the safety and efficacy of long-term ingestion of corn syrup solids containing maltobionic acid on BMD in healthy Japanese women.Methods: A randomized, double-blind, placebo-controlled, parallel-group study was conducted from February to December 2018. Thirty-eight healthy Japanese women aged 50–69 years who were at least 1 year past the onset of natural menopause were allocated to two groups (19 in each group) using a computerized random-number generator: one in which participants ingested 7 g of corn syrup containing maltobionic acid and another in which participants ingested 7 g of placebo (maltose syrup) group per day for 24 weeks. BMD and bone metabolism parameters were measured by DEXA (dual-energy X-ray absorptiometry method) and a peripheral blood test, respectively, while safety was evaluated via a physical examination, peripheral blood test, urinalysis, assessment of subjective symptoms, and a medical questionnaire.Results: Thirty-three subjects completed the study, except for one subject who discontinued the study halfway, and there were no adverse events related to consumption of the test food. Fourteen subjects were excluded before the efficacy analysis because of conflict with control criteria; the remaining 23 subjects were studied (10 in the Test food group and 13 in the Placebo group). Consumption of corn syrup solids containing maltobionic acid was maintained during the intervention period, and BMD, bone mineral content (BMC), and YAM (young adult mean) values were found to be improved (P < 0.05). No safety concerns were observed during the intervention period.Conclusion: These results indicate that the consumption of corn syrup solids containing maltobionic acid may contribute to the prevention of osteoporosis.

scholarly journals Effects of oral intake of heat-killed Lactobacillus brevis SBC8803 (SBL88™) on dry skin conditions: A randomized, double-blind, placebo-controlled study

2016 ◽  
Vol 12 (6) ◽  
pp. 3863-3872 ◽  
Author(s):  
Masahiro Ogawa ◽  
Asako Saiki ◽  
Yuuta Matsui ◽  
Norihiko Tsuchimoto ◽  
Yasukazu Nakakita ◽  
...  
Keyword(s):  
Oral Intake ◽  
Lactobacillus Brevis ◽  
Controlled Study ◽  
Dry Skin ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Skin Conditions
Sign in / Sign up

Export Citation Format

Share Document